SEC Tracker
Get the app

TRex Bio TRXB

TRex Bio announces new shareholder

Ownership stake disclosure by SV Biotech Crossover Opportunities Fund LP

Form
Schedule 13D
Filed
Importance
Notable
  1. Crossover Fund purchased 957,143 shares in IPO at $14.00 per share
  2. Crossover Fund holds 1,920,667 shares, 7.0% of outstanding stock
  3. Crossover Fund held preferred stock converted to 963,524 shares
  4. Reporting Persons may increase or decrease positions based on market conditions

Written from the Schedule 13D on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when TRex Bio files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2836) and public float not reported.

  1. Adaptimmune Therapeutics ADAP
  2. Adverum Biotechnologies ADVM
  3. AgomAb Therapeutics AGMB
  4. Alvotech ALVO
  5. Argenx ARGX